CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...